ST. PAUL, Minn., Jan. 6 /PRNewswire/ -- Nanocopoeia, Inc. has been awarded Small
Business Innovation Research (SBIR) grants totaling $361,000 from the National
Science Foundation (NSF) and the National Institutes of Health (NIH) to prove
the feasibility of its next-generation technology for coating medical stents.
Upon completion of this Phase I research early in 2006, the company becomes
eligible to apply for Phase II follow-on funding totaling more than $2 million.
The grant from NSF, awarded under its Manufacturing Innovation Initiative, funds
development and scale-up of Nanocopoeia's ElectroNanospray(TM) process for applying
nanoparticle-based drug-eluting coatings to coronary stents. The grant from
NIH, awarded under its Bioengineering Nanotechnology program, funds evaluation
of coating performance in terms of controlled drug release and coating integrity.
The SBIR program was established to fund the initial
development stages of groundbreaking technologies
like the ElectroNanospray(TM) process, which moves
substantially beyond the limitations of current,
one-dimensional medical stent coating technology
and enables the next generation of proprietary, multi-
functional stent coatings based on sophisticated,
engineered depositions and coating designs. Under
the SBIR Phase II program, which is designed to prepare
for commercialization with private-sector partners,
Nanocopoeia will focus on process development and
material and process validation. Nanocopoeia is initiating
discussions with potential partners to identify the
best candidate for collaboration on Phase II work
and for commercialization.
market for drug-eluting stents is one of the fastest
growing segments in the medical device industry.
Significant improvement in clinical outcomes associated
with the use of these products is driving the growth.
First- generation products combining therapeutic
drugs with the implantable stents reached the market
in 2004 and have generated in excess of $5 billion
in global sales to date. According to Nanocopoeia's
CEO, Robert A. Hoerr, MD, PhD, "Nanocopoeia expects
that its second-generation, engineered nanocomposite
coating, which could allow for staged and targeted
delivery of therapeutics from the stent surface,
will significantly improve upon the potential for
positive clinical outcomes and will further boost
"We are delighted to be a multiple-SBIR winner," Hoerr
continues. "We understand that this is a highly competitive
review process carried out by expert scientific panels,
and that our selection for multiple awards clearly
validates the promise of our novel approach to coating
Nanocopoeia ( http://www.nanocopoeia.com )
is commercializing its proprietary process for delivering
advanced coatings to the converging industries of
devices, drugs, and delivery. The company's ElectroNanospray(TM)
technology is used to apply polymers and drugs to
medical devices as well as to formulate drugs for
enhanced therapeutic delivery. The Company's business
model is to provide value-added development and formulation
services to corporate partners.
For more details, contact Karen M. Arnold at firstname.lastname@example.org or
Source: Nanocopoeia, Inc.